1
|
Abbasi Shiran J, Kaboudin B, Panahi N, Razzaghi-Asl N. Privileged small molecules against neglected tropical diseases: A perspective from structure activity relationships. Eur J Med Chem 2024; 271:116396. [PMID: 38643671 DOI: 10.1016/j.ejmech.2024.116396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2023] [Revised: 04/02/2024] [Accepted: 04/06/2024] [Indexed: 04/23/2024]
Abstract
Neglected tropical diseases (NTDs) comprise diverse infections with more incidence in tropical/sub-tropical areas. In spite of preventive and therapeutic achievements, NTDs are yet serious threats to the public health. Epidemiological reports of world health organization (WHO) indicate that more than 1.5 billion people are afflicted with at least one NTD type. Among NTDs, leishmaniasis, chagas disease (CD) and human African trypanosomiasis (HAT) result in substantial morbidity and death, particularly within impoverished countries. The statistical facts call for robust efforts to manage the NTDs. Currently, most of the anti-NTD drugs are engaged with drug resistance, lack of efficient vaccines, limited spectrum of pharmacological effect and adverse reactions. To circumvent the issue, numerous scientific efforts have been directed to the synthesis and pharmacological development of chemical compounds as anti-infectious agents. A survey of the anti-NTD agents reveals that the majority of them possess privileged nitrogen, sulfur and oxygen-based heterocyclic structures. In this review, recent achievements in anti-infective small molecules against parasitic NTDs are described, particularly from the SAR (Structure activity relationship) perspective. We also explore current advocating strategies to extend the scope of anti-NTD agents.
Collapse
Affiliation(s)
- J Abbasi Shiran
- Pharmaceutical Sciences Research Center, Ardabil University of Medical Sciences, Ardabil, PO Code: 5618953141, Iran
| | - B Kaboudin
- Department of Chemistry, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan, Iran
| | - N Panahi
- Department of Medicinal Chemistry, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran
| | - N Razzaghi-Asl
- Pharmaceutical Sciences Research Center, Ardabil University of Medical Sciences, Ardabil, PO Code: 5618953141, Iran; Department of Medicinal Chemistry, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran.
| |
Collapse
|
2
|
Freitas de Lima Hercos G, Gabriela Faleiro de Moura Lodi Cruz M, Clara Cassiano Martinho A, de Melo Resende D, Farago Nascimento D, Derksen Macruz P, Jorge Pilau E, Maria Fonseca Murta S, de Oliveira Rezende Júnior C. Optimization of benzenesulfonyl derivatives as anti-Trypanosomatidae agents: Structural design, synthesis, and pharmacological assessment against Trypanosoma cruzi and Leishmania infantum. Bioorg Med Chem 2024; 105:117736. [PMID: 38677111 DOI: 10.1016/j.bmc.2024.117736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2024] [Revised: 03/29/2024] [Accepted: 04/22/2024] [Indexed: 04/29/2024]
Abstract
Leishmaniasis and Chagas disease are neglected tropical diseases caused by Trypanosomatidae parasites. Given the numerous limitations associated with current treatments, such as extended treatment duration, variable efficacy, and severe side effects, there is an urgent imperative to explore novel therapeutic options. This study details the early stages of hit-to-lead optimization for a benzenesulfonyl derivative, denoted as initial hit, against Trypanossoma cruzi (T. cruzi), Leishmania infantum (L. infantum) and Leishmania braziliensis (L. braziliensis). We investigated structure - activity relationships using a series of 26 newly designed derivatives, ultimately yielding potential lead candidates with potent low-micromolar and sub-micromolar activities against T. cruzi and Leishmania spp, respectively, and low in vitro cytotoxicity against mammalian cells. These discoveries emphasize the significant promise of this chemical class in the fight against Chagas disease and leishmaniasis.
Collapse
Affiliation(s)
- Guilherme Freitas de Lima Hercos
- Laboratório de Síntese de Candidatos a Fármacos (LaSFar), Instituto de Química, Universidade Federal de Uberlândia (UFU), Uberlândia, MG 38400-902, Brazil
| | | | - Ana Clara Cassiano Martinho
- Laboratório de Síntese de Candidatos a Fármacos (LaSFar), Instituto de Química, Universidade Federal de Uberlândia (UFU), Uberlândia, MG 38400-902, Brazil
| | - Daniela de Melo Resende
- Grupo de Genômica Funcional de Parasitos, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ Minas), Belo Horizonte, MG 30190-002, Brazil
| | - Danilo Farago Nascimento
- Laboratório de Síntese de Candidatos a Fármacos (LaSFar), Instituto de Química, Universidade Federal de Uberlândia (UFU), Uberlândia, MG 38400-902, Brazil
| | - Paula Derksen Macruz
- Laboratório de Biomoléculas e Espectrometria de Massas (LaBioMass), Universidade Estadual de Maringá (UEM), Maringá, PR 807020-900, Brazil
| | - Eduardo Jorge Pilau
- Laboratório de Biomoléculas e Espectrometria de Massas (LaBioMass), Universidade Estadual de Maringá (UEM), Maringá, PR 807020-900, Brazil
| | - Silvane Maria Fonseca Murta
- Grupo de Genômica Funcional de Parasitos, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ Minas), Belo Horizonte, MG 30190-002, Brazil
| | - Celso de Oliveira Rezende Júnior
- Laboratório de Síntese de Candidatos a Fármacos (LaSFar), Instituto de Química, Universidade Federal de Uberlândia (UFU), Uberlândia, MG 38400-902, Brazil.
| |
Collapse
|
3
|
Klug DM, Tse EG, Silva DG, Cao Y, Charman SA, Chauhan J, Crighton E, Dichiara M, Drake C, Drewry D, da Silva Emery F, Ferrins L, Graves L, Hopkins E, Kresina TAC, Lorente-Macías Á, Perry B, Phipps R, Quiroga B, Quotadamo A, Sabatino GN, Sama A, Schätzlein A, Simpson QJ, Steele J, Shanu-Wilson J, Sjö P, Stapleton P, Swain CJ, Vaideanu A, Xie H, Zuercher W, Todd MH. Open Source Antibiotics: Simple Diarylimidazoles Are Potent against Methicillin-Resistant Staphylococcus aureus. ACS Infect Dis 2023; 9:2423-2435. [PMID: 37991879 PMCID: PMC10714399 DOI: 10.1021/acsinfecdis.3c00286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Revised: 10/30/2023] [Accepted: 10/31/2023] [Indexed: 11/24/2023]
Abstract
Antimicrobial resistance (AMR) is widely acknowledged as one of the most serious public health threats facing the world, yet the private sector finds it challenging to generate much-needed medicines. As an alternative discovery approach, a small array of diarylimidazoles was screened against the ESKAPE pathogens, and the results were made publicly available through the Open Source Antibiotics (OSA) consortium (https://github.com/opensourceantibiotics). Of the 18 compounds tested (at 32 μg/mL), 15 showed >90% growth inhibition activity against methicillin-resistant Staphylococcus aureus (MRSA) alone. In the subsequent hit-to-lead optimization of this chemotype, 147 new heterocyclic compounds containing the diarylimidazole and other core motifs were synthesized and tested against MRSA, and their structure-activity relationships were identified. While potent, these compounds have moderate to high intrinsic clearance and some associated toxicity. The best overall balance of parameters was found with OSA_975, a compound with good potency, good solubility, and reduced intrinsic clearance in rat hepatocytes. We have progressed toward the knowledge of the molecular target of these phenotypically active compounds, with proteomic techniques suggesting TGFBR1 is potentially involved in the mechanism of action. Further development of these compounds toward antimicrobial medicines is available to anyone under the licensing terms of the project.
Collapse
Affiliation(s)
- Dana M. Klug
- School
of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom
| | - Edwin G. Tse
- School
of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom
| | - Daniel G. Silva
- School
of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom
- School
of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo 14040-903. Brazil
| | - Yafeng Cao
- WuXi
AppTec (Wuhan) Co., Ltd., 666 Gaoxin Road, East Lake High-Tech Development Zone, Wuhan 430075, People’s Republic of China
| | - Susan A. Charman
- Centre
for Drug Candidate Optimization, Monash Institute of Pharmaceutical
Sciences, Monash University, Parkville, VIC 3052, Australia
| | - Jyoti Chauhan
- Department
of Chemistry and Chemical Biology, Northeastern
University, Boston, Massachusetts 02115, United States
| | - Elly Crighton
- Centre
for Drug Candidate Optimization, Monash Institute of Pharmaceutical
Sciences, Monash University, Parkville, VIC 3052, Australia
| | - Maria Dichiara
- Department
of Chemistry and Chemical Biology, Northeastern
University, Boston, Massachusetts 02115, United States
| | - Chris Drake
- Hypha Discovery, 154b Brook Dr, Milton, Abingdon OX14 4SD, United Kingdom
| | - David Drewry
- UNC Lineberger
Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
- Structural
Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
| | - Flavio da Silva Emery
- School
of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo 14040-903. Brazil
| | - Lori Ferrins
- Department
of Chemistry and Chemical Biology, Northeastern
University, Boston, Massachusetts 02115, United States
| | - Lee Graves
- Department
of Pharmacology, University of North Carolina
at Chapel Hill, Chapel Hill, North Carolina 27599, United States
| | - Emily Hopkins
- Hypha Discovery, 154b Brook Dr, Milton, Abingdon OX14 4SD, United Kingdom
| | - Thomas A. C. Kresina
- Department
of Chemistry and Chemical Biology, Northeastern
University, Boston, Massachusetts 02115, United States
| | - Álvaro Lorente-Macías
- Department
of Pharmacology, University of North Carolina
at Chapel Hill, Chapel Hill, North Carolina 27599, United States
- Department
of Medicinal & Organic Chemistry and Excellence Research Unit
of ‘‘Chemistry Applied to Biomedicine and the Environment’’,
Faculty of Pharmacy, University of Granada, Campus de Cartuja s/n, 18071 Granada, Spain
- A. L-M.
Cancer Research UK Edinburgh Centre, Institute of Genetics & Cancer, University of Edinburgh, Edinburgh EH4 2XR, United Kingdom
| | - Benjamin Perry
- Drugs
for Neglected Diseases initiative (DNDi), 15 Chemin Camille-Vidart, 1202 Geneva, Switzerland
| | - Richard Phipps
- Hypha Discovery, 154b Brook Dr, Milton, Abingdon OX14 4SD, United Kingdom
| | - Bruno Quiroga
- Department
of Chemistry and Chemical Biology, Northeastern
University, Boston, Massachusetts 02115, United States
| | - Antonio Quotadamo
- Department
of Chemistry and Chemical Biology, Northeastern
University, Boston, Massachusetts 02115, United States
- Clinical
and Experimental Medicine PhD Program, University
of Modena and Reggio Emilia, 41121 Modena, Italy
| | - Giada N. Sabatino
- School
of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom
| | - Anthony Sama
- Citizen
scientist, New York, New York 11570, United States
| | - Andreas Schätzlein
- School
of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom
| | - Quillon J. Simpson
- Department
of Chemistry and Chemical Biology, Northeastern
University, Boston, Massachusetts 02115, United States
| | - Jonathan Steele
- Hypha Discovery, 154b Brook Dr, Milton, Abingdon OX14 4SD, United Kingdom
| | - Julia Shanu-Wilson
- Hypha Discovery, 154b Brook Dr, Milton, Abingdon OX14 4SD, United Kingdom
| | - Peter Sjö
- Drugs
for Neglected Diseases initiative (DNDi), 15 Chemin Camille-Vidart, 1202 Geneva, Switzerland
| | - Paul Stapleton
- School
of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom
| | - Christopher J. Swain
- Cambridge
MedChem Consulting, 8
Mangers Lane, Duxford, Cambridge CB22 4RN, United Kingdom
| | - Alexandra Vaideanu
- School
of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom
| | - Huanxu Xie
- WuXi
AppTec (Wuhan) Co., Ltd., 666 Gaoxin Road, East Lake High-Tech Development Zone, Wuhan 430075, People’s Republic of China
| | - William Zuercher
- UNC Lineberger
Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
| | - Matthew H. Todd
- School
of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom
- Structural
Genomics Consortium, University College
London, 29-39 Brunswick
Square, London WC1N 1AX, United Kingdom
| |
Collapse
|
4
|
Asadi S, Zebarjad M, Mehrabi H. Synthesis of Highly Functionalized Imidazopyridine: A Simple One-Pot Three-Component Synthesis of 6-Hydroxy-5 -(3-Phenylimidazo[1,2- a]Pyridin-2-yl)-2-Thioxo-2, 3-Dihydropyrimidin-4(1H)-Ones. Polycycl Aromat Compd 2023. [DOI: 10.1080/10406638.2022.2161583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Affiliation(s)
- Sara Asadi
- Department of Chemistry, Vali-e-Asr University of Rafsanjan, Rafsanjan, Iran
| | - Maedeh Zebarjad
- Department of Chemistry, Vali-e-Asr University of Rafsanjan, Rafsanjan, Iran
| | - Hossein Mehrabi
- Department of Chemistry, Vali-e-Asr University of Rafsanjan, Rafsanjan, Iran
| |
Collapse
|
5
|
Eco-friendly and regiospecific intramolecular cyclization reactions of cyano and carbonyl groups in N,N-disubstituted cyanamide. Mol Divers 2022; 26:2813-2823. [DOI: 10.1007/s11030-022-10401-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Accepted: 02/05/2022] [Indexed: 12/16/2022]
|
6
|
Mali SN, Pandey A. Balanced QSAR and Molecular Modeling to Identify Structural Requirements of Imidazopyridine Analogues as Anti-infective Agents Against Trypanosomiases. JOURNAL OF COMPUTATIONAL BIOPHYSICS AND CHEMISTRY 2022. [DOI: 10.1142/s2737416521410015] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Human African trypanosomiasis (HAT), a fatal infection caused by Trypanosoma brucei (T. brucei) is considered as a neglected disease in the tropical areas, and newer agents with unique mechanism of action are urgently needed. In this work, 65 Imidazopyridine analogues from known literature were selected for building statistically robust genetic algorithm (GA) based QSAR models. Furthermore, values for the various cross-validation properties supported its statistical robustness (model 1, [Formula: see text], RMSE[Formula: see text], MAE[Formula: see text], CCC[Formula: see text], and [Formula: see text]). Our in silico ADMET analysis revealed that a designed molecule, S10 may act as potent lead (T. brucei, pEC[Formula: see text] ([Formula: see text]M), [Formula: see text]) with better pharmacokinetics, no carcinogenicity, class III acute oral toxicity, minimal OCT1 and OCT2 inhibitions and no eye corrosion profiles. Our molecular docking analysis (on 42 drug targets) for a dataset and designed molecules demonstrated higher binding affinity of Imidazopyridine analogues with T. brucei farnesyl diphosphate synthase (TbFPPS) (PDB id: 2I19). This observation was further supported by 100[Formula: see text]ns molecular dynamics analysis retaining better stability of complex. Thus, imidazopyridine analogues would provide a promising scaffold for the development of anti-HAT agents.
Collapse
Affiliation(s)
- Suraj N. Mali
- Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, India
| | - Anima Pandey
- Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, India
| |
Collapse
|
7
|
Li W, Zhang J, Wang M, Dong R, Zhou X, Zheng X, Sun L. Pyrimidine-fused Dinitrogenous Penta-heterocycles as a Privileged Scaffold for Anti-Cancer Drug Discovery. Curr Top Med Chem 2022; 22:284-304. [PMID: 35021973 DOI: 10.2174/1568026622666220111143949] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Revised: 12/30/2021] [Accepted: 12/30/2021] [Indexed: 11/22/2022]
Abstract
Pyrimidine-fused derivatives that are the inextricable part of DNA and RNA play a key role in the normal life cycle of cells. Pyrimidine-fused dinitrogenous penta-heterocycles including pyrazolopyrimidines and imidazopyrimidines is a special class of pyrimidine-fused compounds contributing to an important portion in anti-cancer drug discovery, which have been discovered as core structure for promising anti-cancer agents used in clinic or clinical evaluations. Pyrimidine-fused dinitrogenous penta-heterocycles have become one privileged scaffold for anti-cancer drug discovery. This review consists of the recent progress of pyrimidine-fused dinitrogenous penta-heterocycles as anti-cancer agents and their synthetic strategies. In addition, this review also summarizes some key structure-activity relationships (SARs) of pyrimidine-fused dinitrogenous penta-heterocycle derivatives as anti-cancer agents.
Collapse
Affiliation(s)
- Wen Li
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| | - Jinyang Zhang
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| | - Min Wang
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| | - Ru Dong
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| | - Xin Zhou
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| | - Xin Zheng
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| | - Liping Sun
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| |
Collapse
|
8
|
N JB, Goudgaon N. A comprehensive review on pyrimidine analogs-versatile scaffold with medicinal and biological potential. J Mol Struct 2021. [DOI: 10.1016/j.molstruc.2021.131168] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
9
|
Silva DG, Feijens P, Hendrickx R, Matheeussen A, Grey L, Caljon G, Maes L, Emery FS, Junker A. Development of Novel Isoindolone-Based Compounds against Trypanosoma brucei rhodesiense. ChemistryOpen 2021; 10:922-927. [PMID: 34553828 PMCID: PMC8459400 DOI: 10.1002/open.202100180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Revised: 09/02/2021] [Indexed: 12/03/2022] Open
Abstract
This study identified the isoindolone ring as a scaffold for novel agents against Trypanosoma brucei rhodesiense and explored the structure-activity relationships of various aromatic ring substitutions. The compounds were evaluated in an integrated in vitro screen. Eight compounds exhibited selective activity against T. b. rhodesiense (IC50 <2.2 μm) with no detectable side activity against T. cruzi and Leishmania infantum. Compound 20 showed low nanomolar potency against T. b. rhodesiense (IC50 =40 nm) and no toxicity against MRC-5 and PMM cell lines and may be regarded as a new lead template for agents against T. b. rhodesiense. The isoindolone-based compounds have the potential to progress into lead optimization in view of their highly selective in vitro potency, absence of cytotoxicity and acceptable metabolic stability. However, the solubility of the compounds represents a limiting factor that should be addressed to improve the physicochemical properties that are required to proceed further in the development of in vivo-active derivatives.
Collapse
Affiliation(s)
- Daniel G. Silva
- QHeteM - Laboratório de Química Heterocíclica e MedicinalSchool of Pharmaceutical Sciences of Ribeirão PretoUniversity of São PauloRibeirão PretoSão Paulo14040-903Brazil
- European Institute for Molecular Imaging (EIMI)Westphalian Wilhelms-University Münster48149MünsterGermany
| | - Pim‐Bart Feijens
- Laboratory of MicrobiologyParasitology and Hygiene (LMPH)University of AntwerpUniversiteitsplein 1Wilrijk B2610Belgium
| | - Rik Hendrickx
- Laboratory of MicrobiologyParasitology and Hygiene (LMPH)University of AntwerpUniversiteitsplein 1Wilrijk B2610Belgium
| | - An Matheeussen
- Laboratory of MicrobiologyParasitology and Hygiene (LMPH)University of AntwerpUniversiteitsplein 1Wilrijk B2610Belgium
| | - Lucie Grey
- Institute for Pharmaceutical and Medicinal ChemistryWestphalian Wilhelms-University Münster48149MünsterGermany
| | - Guy Caljon
- Laboratory of MicrobiologyParasitology and Hygiene (LMPH)University of AntwerpUniversiteitsplein 1Wilrijk B2610Belgium
| | - Louis Maes
- Laboratory of MicrobiologyParasitology and Hygiene (LMPH)University of AntwerpUniversiteitsplein 1Wilrijk B2610Belgium
| | - Flavio S. Emery
- QHeteM - Laboratório de Química Heterocíclica e MedicinalSchool of Pharmaceutical Sciences of Ribeirão PretoUniversity of São PauloRibeirão PretoSão Paulo14040-903Brazil
| | - Anna Junker
- European Institute for Molecular Imaging (EIMI)Westphalian Wilhelms-University Münster48149MünsterGermany
| |
Collapse
|
10
|
Silva DG, Junker A, de Melo SMG, Fumagalli F, Gillespie JR, Molasky N, Buckner FS, Matheeussen A, Caljon G, Maes L, Emery FS. Synthesis and Structure-Activity Relationships of Imidazopyridine/Pyrimidine- and Furopyridine-Based Anti-infective Agents against Trypanosomiases. ChemMedChem 2020; 16:966-975. [PMID: 33078573 PMCID: PMC8048860 DOI: 10.1002/cmdc.202000616] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2020] [Revised: 10/13/2020] [Indexed: 12/22/2022]
Abstract
Neglected tropical diseases remain among the most critical public health concerns in Africa and South America. The drug treatments for these diseases are limited, which invariably leads to fatal cases. Hence, there is an urgent need for new antitrypanosomal drugs. To address this issue, a large number of diverse heterocyclic compounds were prepared. Straightforward synthetic approaches tolerated pre-functionalized structures, giving rise to a structurally diverse set of analogs. We report on a set of 57 heterocyclic compounds with selective activity potential against kinetoplastid parasites. In general, 29 and 19 compounds of the total set could be defined as active against Trypanosoma cruzi and T. brucei brucei, respectively (antitrypanosomal activities <10 μM). The present work discusses the structure-activity relationships of new fused-ring scaffolds based on imidazopyridine/pyrimidine and furopyridine cores. This library of compounds shows significant potential for anti-trypanosomiases drug discovery.
Collapse
Affiliation(s)
- Daniel G Silva
- QHeteM - Laboratório de Química Heterocíclica e Medicinal, School of Pharmaceutical Sciences of Ribeirão Preto - University of São Paulo, Ribeirão Preto, São Paulo, 14040-903, Brazil.,European Institute for Molecular Imaging (EIMI), Westphalian Wilhelms-University, 48149, Münster, Germany
| | - Anna Junker
- European Institute for Molecular Imaging (EIMI), Westphalian Wilhelms-University, 48149, Münster, Germany
| | - Shaiani M G de Melo
- QHeteM - Laboratório de Química Heterocíclica e Medicinal, School of Pharmaceutical Sciences of Ribeirão Preto - University of São Paulo, Ribeirão Preto, São Paulo, 14040-903, Brazil
| | - Fernando Fumagalli
- Centro de Ciências da Saúde (CCS), Universidade Federal de Santa Maria (UFSM), Av. Roraima, 1000, Camobi, Santa Maria, Rio Grande do Sul, 97105-900, Brazil
| | - J Robert Gillespie
- Department of Medicine, University of Washington, Seattle, WA, 98195, USA
| | - Nora Molasky
- Department of Medicine, University of Washington, Seattle, WA, 98195, USA
| | | | - An Matheeussen
- Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, Antwerpen, 2610, Wilrijk, Belgium
| | - Guy Caljon
- Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, Antwerpen, 2610, Wilrijk, Belgium
| | - Louis Maes
- Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, Antwerpen, 2610, Wilrijk, Belgium
| | - Flavio S Emery
- QHeteM - Laboratório de Química Heterocíclica e Medicinal, School of Pharmaceutical Sciences of Ribeirão Preto - University of São Paulo, Ribeirão Preto, São Paulo, 14040-903, Brazil
| |
Collapse
|